Meropenem
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315139

CAS#: 96036-03-2 (free)

Description: Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Zwipen (India, Marketed by Nucleus) Mepem (Taiwan) Meropen (Japan, Korea) and Neopenem (NEOMED India) . It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.

Chemical Structure

img
Meropenem
CAS# 96036-03-2 (free)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 315139
Name: Meropenem
CAS#: 96036-03-2 (free)
Chemical Formula: C17H25N3O5S
Exact Mass: 0.00
Molecular Weight: 383.463
Elemental Analysis: C, 53.25; H, 6.57; N, 10.96; O, 20.86; S, 8.36

Price and Availability

Size Price Availability Quantity
500mg USD 250 2 Weeks
1g USD 450 2 weeks
2g USD 750 2 Weeks
5g USD 1650 2 weeks
10g USD 2950 2 weeks
Bulk inquiry

Related CAS #: 96036-03-2 (free)   119478-56-7 (hydrate)   211238-34-5 (sodium)  

Synonym: Meropenem; ICI 194660; ICI-194660; ICI194660; SM-7338; SM 7338; SM7338; Vabomere.

IUPAC/Chemical Name: (4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

InChi Key: DMJNNHOOLUXYBV-PQTSNVLCSA-N

InChi Code: InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1

SMILES Code: O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

Appearance: White to light yellow crystalline powder.

Purity: >97% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity.
In vitro activity: Meropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. ducreyi. Reference: J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. https://pubmed.ncbi.nlm.nih.gov/2509415/
In vivo activity: Group 3 was injected with meropenem 60 mg/kg/d i.p, group 4 with deferoxamine 80 mg/kg/d s.c and group 5 with combination of these 2 agents at the same doses. While meropenem was started 2 hours later, all treatments were started immediately after the induction of pancreatitis. All rats were killed at the 48th hour of the treatment and blood and tissue samples were collected for amylase determinations, pathologic examinations, and culture. Meropenem significantly reduced the incidence of pancreatic infection. Reference: Pancreas. 2003 Oct;27(3):247-52. https://pubmed.ncbi.nlm.nih.gov/14508131/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Water 77.0 200.80

Preparing Stock Solutions

The following data is based on the product molecular weight 383.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Slaney L, Chubb H, Mohammed Z, Ronald A. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. doi: 10.1093/jac/24.suppl_a.183. PMID: 2509415. 2. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 Suppl A:9-29. doi: 10.1093/jac/24.suppl_a.9. PMID: 2808218. 3. Wang Y, Liu L, Wu Q, Yin Q, Xie F. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. Antibiotics (Basel). 2022 Nov 19;11(11):1660. doi: 10.3390/antibiotics11111660. PMID: 36421304; PMCID: PMC9686672. 4. Ateskan U, Mas MR, Yasar M, Deveci S, Babaoglu E, Comert B, Mas NN, Doruk H, Tasci I, Ozkomur ME, Kocar IH. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52. doi: 10.1097/00006676-200310000-00010. PMID: 14508131.
In vitro protocol: 1. Slaney L, Chubb H, Mohammed Z, Ronald A. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. doi: 10.1093/jac/24.suppl_a.183. PMID: 2509415. 2. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 Suppl A:9-29. doi: 10.1093/jac/24.suppl_a.9. PMID: 2808218.
In vivo protocol: 1. Wang Y, Liu L, Wu Q, Yin Q, Xie F. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. Antibiotics (Basel). 2022 Nov 19;11(11):1660. doi: 10.3390/antibiotics11111660. PMID: 36421304; PMCID: PMC9686672. 2. Ateskan U, Mas MR, Yasar M, Deveci S, Babaoglu E, Comert B, Mas NN, Doruk H, Tasci I, Ozkomur ME, Kocar IH. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52. doi: 10.1097/00006676-200310000-00010. PMID: 14508131.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547861/ PubMed PMID: 31643197.

2: Gibson B. A Brief Review of a New Antibiotic: Meropenem-vaborbactam. Sr Care Pharm. 2019 Mar 1;34(3):187-191. Review. PubMed PMID: 31155025.

3: Albin OR, Patel TS, Kaye KS. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections. Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5. Review. PubMed PMID: 30372359.

4: Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Review. PubMed PMID: 30254477; PubMed Central PMCID: PMC6140735.

5: Wu G, Cheon E. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis. Expert Opin Pharmacother. 2018 Sep;19(13):1495-1502. doi: 10.1080/14656566.2018.1512586. Epub 2018 Aug 30. Review. PubMed PMID: 30160990.

6: Dhillon S. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs. 2018 Aug;78(12):1259-1270. doi: 10.1007/s40265-018-0966-7. Review. Erratum in: Drugs. 2018 Sep;78(13):1383. PubMed PMID: 30128699; PubMed Central PMCID: PMC6132495.

7: Burgos RM, Biagi MJ, Rodvold KA, Danziger LH. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1007-1021. doi: 10.1080/17425255.2018.1511702. Epub 2018 Sep 19. Review. PubMed PMID: 30106599.

8: Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. PLoS One. 2018 Jul 30;13(7):e0201667. doi: 10.1371/journal.pone.0201667. eCollection 2018. Review. PubMed PMID: 30059536; PubMed Central PMCID: PMC6066326.

9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501017/ PubMed PMID: 30000076.

10: Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19. Review. PubMed PMID: 29675787.

11: Cho JC, Zmarlicka MT, Shaeer KM, Pardo J. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination. Ann Pharmacother. 2018 Aug;52(8):769-779. doi: 10.1177/1060028018763288. Epub 2018 Mar 7. Review. PubMed PMID: 29514462.

12: Jorgensen SCJ, Rybak MJ. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28. Review. PubMed PMID: 29427523.

13: McCarthy MW, Walsh TJ. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections. Drugs Today (Barc). 2017 Oct;53(10):521-530. doi: 10.1358/dot.2017.53.10.2721815. Review. PubMed PMID: 29286054.

14: Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:. PubMed PMID: 29230684.

15: Wilby KJ, Nasr ZG, Elazzazy S, Lau TT, Hamad A. A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies. Drugs R D. 2017 Mar;17(1):73-78. doi: 10.1007/s40268-017-0173-0. Review. PubMed PMID: 28101836; PubMed Central PMCID: PMC5318341.

16: Esposito S, Pinzani R, Raffaeli G, Lucchi T, Agostoni C, Principi N. A young infant with transient severe hypertriglyceridemia temporarily associated with meropenem administration: A case report and review of the literature. Medicine (Baltimore). 2016 Sep;95(38):e4872. doi: 10.1097/MD.0000000000004872. Review. PubMed PMID: 27661029; PubMed Central PMCID: PMC5044899.

17: Seija V, Medina Presentado JC, Bado I, Papa Ezdra R, Batista N, Gutierrez C, Guirado M, Vidal M, Nin M, Vignoli R. Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review. Int J Infect Dis. 2015 Jan;30:20-6. doi: 10.1016/j.ijid.2014.09.010. Epub 2014 Oct 30. Review. PubMed PMID: 25447717.

18: Paczkowska M, Garbacki P, Zalewski P, Talaczyńska A, Cielecka-Piontek J. [Meropenem--therapeutic recommendation after twenty years of presence on pharmaceutical market]. Postepy Hig Med Dosw (Online). 2014 May 8;68:441-5. doi: 10.5604/17322693.1101541. Review. Polish. PubMed PMID: 24864096.

19: Scheetz MH, Bolon MK, Esterly JS, Reddy P, Postelnick M, Lee TA. Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. Pharmacotherapy. 2011 May;31(5):469-79. doi: 10.1592/phco.31.5.469. Review. PubMed PMID: 21923428.

20: Perrott J, Mabasa VH, Ensom MH. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother. 2010 Mar;44(3):557-64. doi: 10.1345/aph.1M339. Epub 2010 Feb 2. Review. PubMed PMID: 20124468.